Aegerion Pharmaceuticals, Inc.  

(Public, NASDAQ:AEGR)   Watch this stock  
Find more results for AEGR
31.40
-0.73 (-2.27%)
Oct 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.16 - 32.70
52 week 26.25 - 101.00
Open 32.27
Vol / Avg. 520,018.00/941,654.00
Mkt cap 949.35M
P/E     -
Div/yield     -
EPS -1.76
Shares 29.55M
Beta 0.95
Inst. own 128%
Oct 28, 2014
Q3 2014 Aegerion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Oct 1, 2014
Aegerion Pharmaceuticals Inc at Leerink Rare Disease Roundtable
Sep 8, 2014
Aegerion Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
Aegerion Pharmaceuticals Inc at FBR & Co Inaugural Healthcare Conference
Jul 29, 2014
Q2 2014 Aegerion Pharmaceuticals Inc Earnings Call - Webcast
Jul 29, 2014
Q2 2014 Aegerion Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -26.72% -130.51%
Operating margin -26.15% -128.43%
EBITD margin - -127.45%
Return on average assets -28.45% -55.72%
Return on average equity -36.04% -73.06%
Employees 217 -
CDP Score - -

Address

1 Main St Ste 800
CAMBRIDGE, MA 02142-1531
United States - Map
+1-617-5007867 (Phone)
+1-617-9457968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aegerion Pharmaceuticals, Inc. (Aegerio) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders. As of December 31, 2011, the Company developed its first product candidate, lomitapide, as an oral, once-a-day treatment for patients with a inherited lipid disorder called homozygous familial hypercholesterolemia (HoFH). The Company conducted a 78-week Phase III clinical trial of lomitapide in the treatment of adult patients with HoFH. The 56-week results of the trial were announced in May 2011. It completed the trial during the year ended December 31, 2011, and in January 2012, announced the 78-week results of the trial, which were consistent with the 56-week results. In 2011, the United States Food and Drug Administration (FDA) granted orphan drug designation for lomitapide in the treatment of HoFH.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Marc D. Beer Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Mark J. Fitzpatrick Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Carolina Alarco President, International
Bio & Compensation  - Reuters
Craig Fraser Chief Operating Officer,
Age: 50
Bio & Compensation  - Reuters
Anne Marie Cook Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
Martha J. Carter Senior Vice President, Chief Regulatory Officer
Age: 61
Bio & Compensation  - Reuters
Mark Sumeray M.D. Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Sol J. Barer Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Antonio M. Gotto Jr., M.D., Independent Director
Age: 78
Bio & Compensation  - Reuters